Dr. Liao Yan of Beike Biological R&D Center was awarded the title of “Innovation Expert” among enterprises in Guangdong Province
Posted on
Recently, in accordance with the arrangements of the China Association for Science and Technology to carry out the 2022 enterprise “innovation masters” promotion activities, the Guangdong Association for Science and Technology launched the 2022 Guangdong Province enterprise “innovation masters” selection and promotion activities. Dr. Liao Yan, senior engineer of the R&D Center of Shenzhen Beike Biotechnology Co., Ltd., was awarded the title of “Innovation Expert” among enterprises in Guangdong Province.
It is reported that the selection and promotion of “innovation experts” of enterprises in Guangdong Province is organized to deeply study and implement the spirit of the 19th National Congress of the Communist Party of China and all previous plenary sessions of the 19th Party Congress and the 13th Party Congress of Guangdong Province, strengthen the responsibility of enterprise scientific and technological workers in promoting my country’s scientific and technological independence and self-reliance, innovate organizational mobilization mechanisms, stimulate the innovation vitality of enterprise scientific and technological workers, and enhance the technological innovation capabilities of enterprises. After the activities were submitted by science and technology workers, recommended by provincial science and technology societies and municipal science and technology associations at or above the prefecture level, and reviewed by experts, 100 corporate science and technology workers were identified as the “Innovation Masters” of Guangdong Enterprises in 2022.
Dr. Liao Yan
He is a PhD and postdoctoral fellow in stem cell and tissue engineering at Sun Yat-sen University. He is a high-level professional reserve talent in Shenzhen, a project review expert of the Shenzhen Science and Technology Innovation Commission, and a project review expert of the High-tech Industry Innovation Center of the Shenzhen Development and Reform Commission. He serves as the senior project manager of the R&D center of Shenzhen Beike Biotechnology Co., Ltd. Research results have involved stem cell treatment of diseases such as acute myocardial infarction, Crohn’s disease, lower limb ischemia, viral pneumonia and systemic lupus erythematosus, and more than 20 academic papers have been published in domestic and foreign journals. As the first person in charge, he is responsible for many academic projects such as the National Natural Science Youth Fund, the China Postdoctoral Natural Science Foundation, and the Guangdong Provincial Natural Science Foundation (doctoral startup projects and general projects).
Since joining Beike Biotech, Dr. Liao Yan has been committed to the research and development and registration of stem cell products: on the one hand, in order to improve technical barriers and product performance, font-family: inherit; font-optical-sizing: inherit; font-kerning: inherit; font-feature-settings: inherit; font-variation-settings: inherit; vertical-align: baseline;”>Led the team to start from the direction of enhancing the biological properties of stem cells and reducing the heterogeneity of stem cells. They first developed a new culture process for umbilical cord mesenchymal stem cells, which enhanced the stem cells’ ability to maintain stemness and delay aging. They also developed stem cell “empowerment” technology, which can enhance certain specific functions of mesenchymal stem cells, such as immunosuppression and migration and homing abilities. These research and development directions have been established and carried out in Beike Biotechnology. They are currently in the pre-clinical research stage and have applied for three related invention patents to the Patent Office. On the other hand, under the guidance of the National Stem Cell Product Application Guidelines, Actively participate in the process development and pharmacological and toxicological evaluation of Beike Bio’s umbilical cord mesenchymal stem cell injection product, and participate in submitting IND applications to the Food and Drug Administration.
In the future, Dr. Liao Yan will work with Beike Biotech to complete the planThe IND application for umbilical cord mesenchymal stem cell injection products will promote the development of clinical trials on 1-2 indications; efforts will be made to apply for IND for second-generation products such as “empowering stem cells”, and ultimately be transformed and implemented. In addition, the heterogeneity of mesenchymal stem cells affects the stability and quality of their products. Currently, the team of Dr. Liao Yan of Beike Biotech is developing Induced pluripotent stem cell (iPSC) technology, and iMSCs cell products derived from iPSC differentiation will achieve large-scale production, good stability and strong functional product features, and will have broad development space in the future.
Innovation is the first driving force leading the development of science and technology. Beike Biotechnology will continue to implement the strategy of innovation-driven development in depth, continuously increase the construction of corporate platforms around the needs of the cell industry, gather high-end talents, technologies and facilities and other scientific and technological R&D innovation elements, and continue to move towards becoming an enterprise with core competitiveness in the field of stem cells.
